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BACKGROUND
Face-mask ventilation is the most common resuscitation method for birth as-
phyxia. Ventilation with a cuffless laryngeal mask airway (LMA) has potential 
advantages over face-mask ventilation during neonatal resuscitation in low-income 
countries, but whether the use of an LMA reduces mortality and morbidity among 
neonates with asphyxia is unknown.
METHODS
In this phase 3, open-label, superiority trial in Uganda, we randomly assigned 
neonates who required positive-pressure ventilation to be treated by a midwife 
with an LMA or with face-mask ventilation. All the neonates had an estimated 
gestational age of at least 34 weeks, an estimated birth weight of at least 2000 g, 
or both. The primary outcome was a composite of death within 7 days or admis-
sion to the neonatal intensive care unit (NICU) with moderate-to-severe hypoxic–
ischemic encephalopathy at day 1 to 5 during hospitalization.
RESULTS
Complete follow-up data were available for 99.2% of the neonates. A primary out-
come event occurred in 154 of 563 neonates (27.4%) in the LMA group and 144 of 
591 (24.4%) in the face-mask group (adjusted relative risk, 1.16; 95% confidence 
interval [CI], 0.90 to 1.51; P = 0.26). Death within 7 days occurred in 21.7% of the 
neonates in the LMA group and 18.4% of those in the face-mask group (adjusted 
relative risk, 1.21; 95% CI, 0.90 to 1.63), and admission to the NICU with moder-
ate-to-severe hypoxic–ischemic encephalopathy at day 1 to 5 during hospitalization 
occurred in 11.2% and 10.1%, respectively (adjusted relative risk, 1.27; 95% CI, 
0.84 to 1.93). Findings were materially unchanged in a sensitivity analysis in which 
neonates with missing data were counted as having had a primary outcome event 
in the LMA group and as not having had such an event in the face-mask group. 
The frequency of predefined intervention-related adverse events was similar in the 
two groups.
CONCLUSIONS
In neonates with asphyxia, the LMA was safe in the hands of midwives but was 
not superior to face-mask ventilation with respect to early neonatal death and 
moderate-to-severe hypoxic–ischemic encephalopathy. (Funded by the Research 
Council of Norway and the Center for Intervention Science in Maternal and Child 
Health; NeoSupra ClinicalTrials.gov number, NCT03133572.)
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Approximately 7 million neonates worldwide need resuscitation at birth.1 Birth asphyxia is the third leading cause 
of neonatal death, accounting for approximately 
700,000 deaths each year.2,3 Wide-scale imple-
mentation of evidence-based interventions has 
improved perinatal outcomes, but United Nations 
Sustainable Development Goal 3 emphasizes the 
need to accelerate the reduction of neonatal 
mortality. According to this global goal, each 
country should aim for a neonatal mortality 
below 12 per 1000 live births by 2030.4 Improv-
ing outcomes from neonatal resuscitation is 
crucial to achieve this target.5
Effective positive-pressure ventilation is the 
most important step in neonatal resuscitation.6,7 
A modeling study estimated that proper bag-and-
mask ventilation could reduce intrapartum-related 
mortality by 40%.8 However, delivering proper 
tidal volumes with a face mask is difficult. Mask 
leakage, airway blockage, and poor chest expan-
sion have been reported.9-11 Ventilation is com-
monly initiated with a face mask, followed by 
endotracheal intubation in the event of a failure 
of face-mask ventilation or a need for prolonged 
ventilatory support. Endotracheal intubation is 
the most difficult skill in neonatal resuscitation, 
and a study showed a success rate of 24% among 
residents, 78% among fellows, and 86% among 
consultants.12
International guidelines have suggested the 
use of the laryngeal mask airway (LMA) in cases 
of failure of positive-pressure ventilation with 
the use of a face mask during resuscitation of 
neonates (gestational age of ≥34 weeks, birth 
weight of ≥2000 g, or both) or if intubation is 
unsuccessful or not feasible.13,14 Studies suggest 
that effective positive-pressure ventilation can be 
performed safely with the LMA in most neonates 
(range, 95 to 99%) and thus reduce the need for 
intubation.15-18
Most neonates with asphyxia in low-income 
countries receive no advanced airway manage-
ment,5 so shifting the use of the LMA to nondoc-
tors could improve outcomes. The effectiveness 
and safety of the LMA as compared with the face 
mask have been identified as important knowl-
edge gaps.13,19 In the Neonatal Supraglottic Air-
way (NeoSupra) trial, we wanted to test the hy-
pothesis that the LMA would be superior to the 
face mask with respect to mortality and morbid-
ity among neonates with asphyxia when used as 
a primary device for neonatal resuscitation by 
midwives in a low-income country.
Me thods
Trial Oversight
Our trial was an investigator-initiated, single-site, 
randomized, phase 3, open-label, superiority, 
controlled trial involving neonates who needed 
positive-pressure ventilation at birth in two par-
allel groups: resuscitation with an LMA (i-gel, 
size 1, Intersurgical)20 or with a face mask 
(round-shaped, silicone, size 1, Laerdal Medical). 
The trial was conducted at the Mulago National 
Referral Hospital in Kampala, Uganda, where 
practitioners assist in approximately 25,000 de-
liveries annually. Treatments that were available 
in the neonatal intensive care unit (NICU) in-
cluded the use of supplemental oxygen and nasal 
continuous positive airway pressure; mechanical 
ventilators and continuous monitoring were not 
available.
The trial protocol has been published previ-
ously.21 The protocol and statistical analysis plan 
are available with the full text of this article at 
NEJM.org. The protocol was approved by the 
Uganda National Council for Science and Tech-
nology and the Regional Committee for Medical 
and Health Research Ethics in Norway. The 
manufacturers of the laryngeal mask airway and 
the face mask did not provide support for the 
trial and were not involved its design or conduct 
or in the writing of the manuscript. The spon-
sors (the Research Council of Norway and the 
Center for Intervention Science in Maternal and 
Child Health) had no influence on the design or 
conduct of the trial and were not involved in data 
collection or analysis, in the writing of the 
manuscript, or in the decision to submit it for 
publication. There were no agreements concern-
ing confidentiality of the data between the spon-
sors and the authors or their institutions.
A two-tier procedure for consent was used 
because the trial involved the care of unexpect-
edly critically ill neonates. Mothers entering the 
labor ward received brief oral information about 
the trial and provided oral consent. Mothers 
whose neonates were found to be eligible were 
approached for deferred written consent for con-
tinuing participation.
An independent data monitoring committee 
operated according to the procedures used by 
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the DAMOCLES (Data Monitoring Committees: 
Lessons, Ethics, Statistics) Study Group.22 A pre-
specified interim analysis that was performed in 
January 2019 allowed the trial to be continued. 
The trial was conducted in accordance with the 
principles of the Declaration of Helsinki. The 
first, second, sixth, tenth, and last authors as-
sume responsibility for the accuracy and com-
pleteness of the data and for the fidelity of the 
trial to the protocol.
Participants
Neonates were eligible for inclusion in the trial 
if they were born in the hospital; had an esti-
mated gestational age of at least 34 weeks, an 
estimated birth weight of at least 2000 g, or 
both; and required positive-pressure ventilation 
at birth. Neonates with major malformations 
(incompatible with sustained life or affecting 
the airways) and stillbirths were excluded.
On a daily basis, investigators and trained 
research assistants consecutively recruited neo-
nates around the clock until the required sample 
size was reached. Among stillborn neonates 
(those born with no heart rate and no breathing 
efforts), fresh stillborn neonates (those without 
maceration) received at least 10 minutes of ven-
tilation, and stillborn neonates with macera-
tion grade 0 or grade I (“parboiled” reddened skin 
or skin slippage and peeling) received at least 
1 minute of ventilation.23 Enrolled neonates and 
their mothers were tagged with a trial identifica-
tion number on a bracelet.
Trial Procedures
Day-by-day cluster randomization was performed 
for practical reasons; the randomization proce-
dure was prepared by an independent statistician 
with the use of randomly selected block sizes of 
four to eight. The assignments remained con-
cealed in opaque, sealed, and dated envelopes, 
pending the actual date of randomization. The 
device that was not assigned for the day was 
available in a sealed box. Midwives were in-
structed to continue ventilation with the device 
of the day for 3 minutes and, if ventilation was 
inadequate, to reposition the LMA or reapply the 
face mask before a switch to the other device 
was considered. The decision to switch was based 
on recommendations from the International 
Liaison Committee on Resuscitation (ILCOR).24 
A report that specified the reason for switching 
was filed in every case.
Before the initiation of the trial, all the mid-
wives who were involved in neonatal resuscita-
tion (approximately 200 persons) participated in 
a 1-day training session based on the second 
edition of the Helping Babies Breathe (HBB) cur-
riculum, including practice with face-mask ven-
tilation, with an additional module for using the 
LMA in a mannequin (SimNewB, Laerdal Medi-
cal).25 Two pediatricians who were trained in use 
of the LMA conducted the training, facilitated by 
local HBB instructors. Three successful LMA 
insertions in the mannequins as shown by effec-
tive ventilation were required. Repeated HBB 
and on-site training were given throughout the 
trial to new providers to correctly recognize the 
need for positive-pressure ventilation and to sup-
port the management of resuscitation, LMA and 
face-mask use, and adherence to the protocol.
The severity of hypoxic–ischemic encepha-
lopathy was assessed according to the Thomp-
son score, a validated clinical and prognostic 
tool for hypoxic–ischemic encephalopathy that 
is used in settings where sophisticated technol-
ogy is unavailable.26,27 Scoring is based on nine 
items including muscle tone, level of conscious-
ness, clinically apparent seizures, posture, the 
presence of primitive reflexes (Moro, grasp, and 
suck), respiratory pattern, and fontanel tension; 
scores ranges from 0 to 22 (with 0 indicating 
normal, 1 to 10 mild hypoxic–ischemic encepha-
lopathy, 11 to 14 moderate hypoxic–ischemic 
encephalopathy, and 15 to 22 severe hypoxic–
ischemic encephalopathy) (Table S3 in the Sup-
plementary Appendix, available at NEJM.org).28 
Research assistants who extracted data from 
clinical records and observed each resuscitation 
were aware of the trial-group assignments, and 
the data monitoring committee had access to 
information about trial-group assignments dur-
ing the interim analysis and the assessment of 
serious adverse events and adverse events. NICU 
physicians who assessed outcomes and the stat-
istician who analyzed the data were unaware of 
the trial-group assignments.
Interventions
HBB principles of the Golden Minute were ap-
plied to all the neonates in need of positive-
pressure ventilation, including drying, stimula-
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tion, and assessment.25,29 A research assistant 
started a stopwatch at the time of birth. Any 
infant who was not breathing after the initial 
steps had the umbilical cord cut and was moved 
to the resuscitation area for initiation of posi-
tive-pressure ventilation. Inflations were admin-
istered with ambient air with a 240-ml silicone 
self-inflating bag and a pressure-relief valve 
limit at 35 to 40 cm of water (NeoNatalie Resus-
citator, Laerdal Medical). All the neonates with a 
5-minute Apgar score of less than 7 and persist-
ing respiratory distress or signs of hypoxic–
ische mic encephalopathy were transferred to the 
NICU. Advanced resuscitation (endotracheal in-
tubation, chest compressions, or both) was initi-
ated if a physician was available. Resuscitations 
were continuously monitored by research assis-
tants and video-recorded with the use of an HD 
1080P Black Box AI-IP018 camera (Shenzhen 
Aishine Electronics), and the recordings were 
reviewed daily by trial physicians.
Outcomes
The primary outcome was a composite of death 
within 7 days or admission to the NICU with 
moderate-to-severe hypoxic–ischemic encepha-
lopathy (Thompson score, ≥11) at day 1 to 5 
during hospitalization.28 The secondary out-
comes were the safety of the LMA in the hands 
of midwives, based on clinical and video obser-
vations; the need for advanced resuscitation; 
early neonatal death (within 7 days of life); very 
early neonatal death (within 24 hours of life); 
admission to the NICU with moderate-to-severe 
hypoxic–ischemic encephalopathy at day 1 to 5 
during hospitalization; admission to the NICU 
with mild-to-severe hypoxic–ischemic encepha-
lopathy (Thompson score ≥7) at day 1 to 5 dur-
ing hospitalization; and any hospital admission 
during the first 7 days of life.30 Recorded adverse 
events included predefined intervention-related 
adverse events and serious adverse events, as 
well as other adverse events and serious adverse 
events.
Statistical Analysis
A relative between-group difference of 25% in 
the primary outcome measure was considered to 
be clinically relevant for changing clinical prac-
tice. A sample size of 954 neonates was required 
for a 90% chance of detecting an absolute differ-
ence of 10 percentage points in the primary 
outcome (30% in the LMA group vs. 40% in the 
face-mask group) at a two-sided significance 
level of 5%. The sample size was increased to 
1150 to account for day-by-day cluster random-
ization, under the assumption of an intraclass 
correlation coefficient of 0.10 and an average 
daily enrollment of 3 neonates.
The statistical analysis was performed on an 
intention-to-treat basis. Our protocol also speci-
fied a per-protocol analysis and a crossover-
adjusted intention-to-treat analysis; however, 
because crossover between the groups (i.e., 
switch to the other device) occurred for safety 
reasons at the discretion of the provider and was 
likely to be associated with poorer outcomes, we 
decided before unblinding not to perform these 
analyses.
Categorical data were recorded as frequency 
and percentage. Continuous data were recorded 
as median and interquartile range. The statisti-
cal analysis included both unadjusted and ad-
justed analyses. Outcome measures were com-
pared between the groups with the use of the 
chi-square test or Fisher’s exact test (unadjusted 
analysis). Generalized mixed-effects models were 
used to estimate the effect of the treatment on 
outcome measures, with adjustment for clusters 
(random effect) and unbalanced neonate charac-
teristics (adjusted analysis). Effect sizes were 
reported as relative risk with 95% confidence 
interval.
Missing data were very rare; hence, the main 
analysis was based on cases with complete data 
(available in 99.2% of the neonates). A post hoc 
sensitivity analysis (in which neonates with 
missing data were counted as having had a pri-
mary outcome event in the LMA group and as 
not having had such an event in the face-mask 
group) was also performed.
All tests were two-sided, and a P value of less 
than 0.05 was considered to indicate statistical 
significance. Data were analyzed with the use of 
R software, version 3.5 (R Foundation for Statis-
tical Computing).31
R esult s
Characteristics of the Neonates
From May 8, 2018, through August 12, 2019, we 
determined that of the 16,791 neonates who 
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Figure 1. Enrollment and Randomization of the Participants.
17,505 Neonates were eligible
16,791 Had mother who provided
oral consent 
651 Had mother who declined oral consent
63 Had mother who was in second
stage of labor
1439 Were in need of positive-
pressure ventilation
268 Were excluded
229 Did not meet inclusion criteria
165 Were premature
25 Had major malformations
39 Were born outside of hospital
39 Had mother who did not provide deferred
written consent
8 Had mother who declined to provide
consent
14 Had mother with eclampsia
8 Had mother with language barrier
6 Had mother who died before
providing consent
3 Had mother who was mentally
unstable
1171 Underwent randomization
8 Were withdrawn from trial after video
review
4 Were fresh stillbirths
2 Did not need positive-pressure ventilation
2 Had major dysmorphic features 
566 Were assigned to laryngeal mask airway
546 Received assigned intervention
20 Did not receive assigned intervention
19 Were switched to face mask
1 Was switched multiple times and ended up
with laryngeal mask airway
597 Were assigned to face mask
532 Received assigned intervention
65 Did not receive assigned intervention
63 Were switched to laryngeal mask airway
1 Was switched multiple times and ended up
with face mask
1 Was switched multiple times and ended up
with laryngeal mask airway
3 Were lost to follow-up 6 Were lost to follow-up
563 Were included in the analysis 591 Were included in the analysis
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were eligible to participate in the trial and for 
whom the mother had provided oral consent, 
1439 (8.6%) needed positive-pressure ventilation, 
and 1171 who fulfilled the inclusion criteria 
underwent randomization (Fig. 1). After video 
review, 8 neonates who did not meet the inclu-
sion criteria were excluded, and 1163 (717 male 
and 446 female neonates; median birth weight, 
3100 g) were assigned to either the LMA group 
(566 neonates) or the face-mask group (597 neo-
nates). The two groups were well-balanced with 
respect to all baseline characteristics except for 
sex (Table 1); sex was thus included as a covari-
ate in the adjusted analyses. Nine neonates were 
lost to follow-up, so 1154 neonates (563 in the 
LMA group and 591 in the face-mask group) 
were included in the primary analysis.
Crossover to the other device occurred in 20 
of 566 neonates (3.5%) in the LMA group and 65 
of 597 neonates (10.9%) in the face-mask group 
(relative risk, 0.32; 95% confidence interval [CI], 
0.20 to 0.53); after the use of the initial device, 
these crossovers occurred after a median dura-
tion of 11 minutes (interquartile range, 4 to 26) 
in the LMA group and 8 minutes (interquartile 
range, 6 to 11) in the face-mask group. The most 
common reasons for crossover were lack of or 
poor chest movement (44 of 85 [52%]) and lack 
of or poor heart-rate improvement (35 of 85 
[41%]) (Table S1).
Primary Outcome
A primary outcome event occurred in 154 of 563 
neonates (27.4%) in the LMA group (122 deaths 
and 32 cases of moderate-to-severe hypoxic–
ischemic encephalopathy) and 144 of 591 (24.4%) 
in the face-mask group (109 deaths and 35 cases 
of moderate-to-severe hypoxic–ischemic enceph-
alopathy) (unadjusted relative risk, 1.12; 95% CI, 
0.92 to 1.37; adjusted relative risk, 1.16; 95% CI, 
0.90 to 1.51) (Table 2 and Table S2). Results of 
the sensitivity analysis (in which neonates with 
missing data were counted as having had a pri-
mary outcome event in the LMA group and as 
not having had such an event in the face-mask 
group) were similar to the findings in the pri-
mary analysis (unadjusted relative risk, 1.15; 
95% CI, 0.95 to 1.40; adjusted relative risk, 1.20; 
95% CI, 0.92 to 1.55).
Secondary Outcomes and Safety
There was no evidence that any of the secondary 
outcome measures differed substantially be-
tween the two groups (Table 2). Early neonatal 
deaths (within 7 days) according to treatment 
sequence (including a switch to the other device 
and advanced resuscitation) are shown in Figure 
S1. Among the neonates who underwent cross-
over, the percentage who had a primary outcome 
event was 90% (18 of 20) for those starting with 
the LMA who switched to the face mask, as 
compared with 68% (44 of 65) for those starting 
with the face mask who switched to the LMA 
(relative risk, 1.33; 95% CI, 1.06 to 1.66) (Table 
S1). Few predefined potentially intervention-







Median maternal age (IQR) — yr 24 (21–29) 23 (20–28)
≥1 Antenatal visit — no. (%) 563 (99.5) 588 (98.5)
Primiparous — no. (%) 255 (45.1) 268 (44.9)
Amniotic fluid — no. (%)
Clear 205 (36.2) 216 (36.2)
Meconium­stained, foul­smelling,  
or both
342 (60.4) 370 (62.0)
Unknown 19 (3.4) 11 (1.8)
Type of delivery — no. (%)
Vaginal delivery 249 (44.0) 268 (44.9)
Vaginal delivery by vacuum extraction 18 (3.2) 28 (4.7)
Cesarean section 299 (52.8) 301 (50.4)
Male sex — no. (%) 368 (65.0) 349 (58.5)
Multiple birth — no. (%) 37 (6.5) 30 (5.0)




Median time to resuscitation table (IQR) 
— sec†
47 (28–97) 52 (29–103)
Median Apgar score (IQR)
At 1 min 3 (2–4) 3 (2–4)
At 5 min 5 (4–6) 5 (4–6)
At 10 min 7 (6–8) 7 (6–8)
*  IQR denotes interquartile range.
†  Data on time to the resuscitation table were unavailable for one participant 
assigned to the laryngeal mask airway and two participants assigned to the 
face mask.
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related adverse events occurred overall, with no 
significant difference between the two groups 
(Table 3).
Discussion
This randomized trial of the effectiveness and 
safety of the LMA in neonatal resuscitation con-
ducted by midwives in a low-income country 
showed the LMA to be safe in the hands of 
midwives but to confer no benefit over the face 
mask with respect to the composite of early neo-
natal death or moderate-to-severe hypoxic–
ische mic encephalopathy. The cuffless LMA that 
was used in this trial is designed to provide an 
efficient seal to the larynx without the inflatable 
cuff used in conventional LMAs. Positioning is 
easy, and the risk of tissue compression or dis-
lodgement is low.16,32 Thus, the device provides 
a useful alternative to the face mask and endo-
tracheal intubation, especially in settings where 
skills in performing positive-pressure ventila-
tion or intubation are insufficient.5 A study in 
Uganda that used mannequins showed that 
after a brief training, midwives could easily 
insert this LMA, and it was more effective than 
the face mask in establishing positive-pressure 
ventilation in a mannequin.33 A phase 2, random-
ized, controlled trial at the same site showed 
that midwives could perform resuscitation in 
neonates effectively and safely with the cuff-
less LMA.34
Data from previous trials have suggested that 
LMA use results in shorter ventilation times than 
use of a face mask and may reduce the hypoxic–
ischemic insult.15,16,34 Resuscitations in these 
studies were conducted by physicians or super-
vised midwives. In the present trial, midwives 
used the LMA unsupervised, and the insertion 
technique could have been suboptimal, which 
may have affected the effectiveness of the LMA. 
The observation of a higher likelihood of treat-
ment failure in the face-mask group than in the 
LMA group and the suggestion that rescue with 
the LMA might result in better outcomes than 
rescue with the face mask in the current trial are 
consistent with the results from previous tri-
als.17,18,34 The frequency of failure with the face 
mask appeared to be lower than in our pilot 
trial; this may reflect improved skills regarding 
face-mask ventilation among midwives because of 
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Although our trial did not show superiority of 
the LMA over the face mask and the trial was 
not designed to assess noninferiority, the find-
ings appear consistent with current ILCOR rec-
ommendations.24 Thus, our findings suggest 
that the LMA can be safely used as an alternative 
device during newborn resuscitation, including 
when performed by trained midwives.
Most studies show that 3 to 6% of neonates 
require positive-pressure ventilation at birth. In 
our trial, 8.6% needed positive-pressure ventila-
tion, and a large proportion of neonates were 
severely compromised; 61.2% had meconium-
stained or foul-smelling amniotic fluid, and very 
early neonatal death occurred in 15.1%. This 
percentage is considerably higher than those in 
previous reports35,36 and could reflect the hospi-
tal demographics, with large numbers of late 
referrals and mainly neonates with severe as-
phyxia; previous reports that showed benefits of 
the LMA largely involved neonates who had mild 
asphyxia.15,17,18,35 Differences between our trial 
population and those in previous trials are a 
potential explanation for the discrepancy be-
tween our results and the results of previous 
trials.
This trial extends our knowledge about LMA 
use among severely compromised neonates in a 
low-income setting — where more neonatal 
deaths occur than in higher-income settings and 
advanced resuscitation is often not available — 
by having a larger number of participants, rele-
vant outcomes, rigorous methods (including 
video documentation), and a strong adherence to 
trial-group assignments with minimal loss to 
follow-up or exclusions. The trial also has some 
limitations. It was a single-site trial in a high-
volume hospital, where fetal heart-rate monitor-
ing was not routinely available, and there was 
inconsistent capacity of staff to provide ad-
vanced resuscitation; thus, the findings may not 
be generalizable to better-resourced settings. 
For trial conduct, we had additional staff on site. 
Crossovers, which occurred for safety reasons, 
were more frequent in the face-mask group than 
in the LMA group (10.9% vs. 3.5%), and this 
might have improved the outcomes of the neo-
nates initially treated with the face mask. The 
neurologic outcome (hypoxic–ischemic encepha-
lopathy) was based on the Thompson score 
without advanced examinations (e.g., electroen-
cephalography or neuroimaging). In addition, it 
was an open-label trial, but hard outcomes were 
used and outcome assessors were not aware of 
the trial-group assignments.
In our trial, the LMA was safe in the hands 
of midwives but did not result in a lower inci-
dence of early neonatal death or moderate-to-
severe hypoxic–ischemic encephalopathy than 
face-mask ventilation among neonates with as-
phyxia.
Supported by unrestricted grants from the Research Council 
of Norway (grant 250531) and the Center for Intervention Sci-
ence in Maternal and Child Health (project number 223269), 
Norway. In-kind contributions were made by the University of 
Bergen and Stavanger University Hospital, Norway; Makerere 
University, Uganda; Karolinska Institutet and Sachs’ Children 
and Youth Hospital, Sweden; and Padua University, Italy.
No potential conflict of interest relevant to this article was 
reported.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
Table 3. Adverse Events and Severe Adverse Events at Resuscitation  
and in the Hospital within 7 Days.*
Event
Laryngeal 




Blood from mouth† 2/566 (0.4) 2/597 (0.3) 0.99
Vomiting† 0/566 0/597 —
Other adverse event 0/566 0/597 —
In the hospital within 7 days
Bleeding† 1/472 (0.2) 1/497 (0.2) 0.99
Localized infection† 1/472 (0.2) 1/497 (0.2) 0.99
Severe adverse events
At resuscitation
Laryngospasm† 0/566 0/597 —
In the hospital within 7 days
Stridor† 0/472 0/497 —
Airway obstruction† 0/472 0/497 —
Visible trauma† 0/472 0/497 —
Sepsis†‡ 1/472 (0.2) 0/497 0.49
Omphalitis 1/472 (0.2) 0/497 0.49
*  P values are unadjusted. Adjusted analysis was not performed owing to the 
small number of occurrences of the outcomes.
†  This event was prespecified in the trial protocol.
‡  Sepsis was based on clinical report. Antibiotics were routinely prescribed to 
neonates with asphyxia, and there was limited diagnostic testing capacity to 
evaluate for sepsis.
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